SynthesisSensors (Basel, Switzerland)2026
From Single-Modal to Multi-Modal Artificial Intelligence in Alzheimer's Disease: A Systematic Review of Databases, Modalities, Diagnostic Performance, and Clinical Translation Challenges.
Synthesis in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Alzheimer's disease (AD) is the leading cause of dementia and a major cause of death worldwide, making early detection a critical clinical priority. Because pathological changes may begin 15-20 years before symptom onset, artificial intelligence (AI) has emerged as a promising tool for identifying and characterizing AD. In particular, multi-modal approaches that integrate cognitive, biological, and sensor-based data have attracted growing interest. This systematic review compares single- and multi-modal AI strategies for AD detection, covering machine learning and deep learning methods, feature representations, validation strategies, and classification tasks. Searches of major databases identified 568 studies published between 2016 and early 2026; 278 met the inclusion criteria according to PRISMA guidelines. Multi-modal approaches generally achieved higher performance than single-modal strategies, particularly for challenging tasks such as predicting progression between closely related disease stages, although direct comparisons under identical conditions remain scarce. Critically, only about 4% of studies evaluated their models on a genuinely independent external cohort, raising substantial concerns about model generalizability. Overall, current AI systems remain highly dependent on existing datasets and heterogeneous evaluation protocols, which limit generalizability and clinical applicability. Future research should prioritize representative multimodal datasets, rigorous external validation, and clinically interpretable AI systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.